The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1491
March 28, 2016
View Complete Issue         Table of Contents 2019 
Lumacaftor/Ivacaftor (Orkambi) for Cystic Fibrosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lumacaftor/Ivacaftor (Orkambi) for Cystic Fibrosis
March 28, 2016 (Issue: 1491)
The FDA has approved a fixed-dose combination of lumacaftor and ivacaftor (Orkambi – Vertex) for oral treatment of cystic fibrosis (CF) in patients ≥12 years old who are homozygous for the F508del mutation. About 50% of patients in the US...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lumacaftor/Ivacaftor (Orkambi) for Cystic Fibrosis
Article code: 1491b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.